Study of urinary 6β-hydroxycortisol/cortisol ratio in spot urine sample as a biomarker of 3A4 enzyme activity in healthy and epileptic subjects of Egyptian population

Pharmacological Research

Volumn 51, Issue 6, 2005, Pages 575-580

  El Desoky, Ehab S ^a   Mohamed, Hanan O ^a   Farghaly, Wafaa M A ^a   Hamed, Sherifa A ^a   Hedaya, Mohsen A ^b   Siest, Jean Pascal ^c  

^a Assiut University Faculty of Medicine   (Egypt)

^b Tanta University   (Egypt)

^c STABILIGEN   (France)

Author keywords

6 Hydroxycortisol cortisol ratio; Carbamazepine; CYP3A4

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; BIOLOGICAL MARKER; CARBAMAZEPINE; CYTOCHROME P450 3A4; HYDROCORTISONE;

ADOLESCENT; ADULT; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPILEPSY; FEMALE; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; STEROID URINE LEVEL; URINALYSIS;

EID: 17044375397     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2005.02.014     Document Type: Article

References (51)

1. Y. Caraco Genetic determinants of drug responsiveness and drug interactions Ther Drug Monit 20 1998 517 524
2. E. Tanaka Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes J Clin Pharm Ther 23 1998 403 416
3. E. Spina, and E. Perucca Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs Epilepsia 43 Suppl. 2 2002 37 44
4. C. Finta, and P.G. Zaphiropoulos The human cytochrome P4503A locus. Gene evolution by capture of downstream exons Gene 260 2000 13 23
5. K. Gellner, R. Eiselt, E. Hustert, H. Arnold, and I. Koch Genomic organization of the human CYP3A locus: identification of a new inducible CYP3A gene Pharmacogenetics 11 2001 111 121
6. P.B. Watkins, S.A. Wrighton, E.G. Schuetz, D.T. Molowa, and P.S. Guzelian Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man J Clin Invest 80 1987 1029 1036
7. M. Komori, K. Nishio, M. Kitada, K. Shiramatsu, and K. Muroya Fetus-specific expression of a form of cytochrome P-450 in human livers Biochemistry 29 1990 4430 4433
8. T. Aoyama, S. Yamano, D.J. Waxman, D.P. Lapenson, and U.A. Meyer Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine J Biol Chem 264 1989 10388 10395
9. E.G. Schuetz, J.D. Schuetz, W.M. Grogan, A. Naray-Fejes-Toth, and G. Fejes-Toth Expression of cytochrome P4503A in amphibian, rat, and human kidney Arch Biochem Biophys 294 1992 206 214
10. S. Anttila, J. Hukkanen, J. Hakkola, T. Stjernvall, and P. Beaune Expression and localization of CYP3A4 and CYP3A5 in human lung Am J Respir Cell Mol Biol 16 1997 242 249
11. M.M. Galteau, and F. Shamsa Urinary 6β-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals Eur J Clin Pharmacol 59 2003 713 733
12. A.P. Li, D.L. Kaminski, and A. Rasmussen Substrates of human hepatic cytochrome P4503A4 Toxicology 104 1995 1 8
13. W.R. Brian, M.A. Sari, M. Iwasaki, T. Shimada, and L.S. Kaminsky Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae Biochemistry 29 1990 11280 11292
14. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F.P. Guengerich Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians J Pharmacol Exp Ther 270 1994 414 423
15. E. Hustert, M. Haberl, O. Burk, R. Wolbold, and Y.Q. He The genetic determinants of the CYP3A5 polymorphism Pharmacogenetics 11 2001 773 779
16. Y.S. Lin, A.L. Dowling, S.D. Quigley, F.M. Farin, and J. Zhang Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism Mol Pharmacol 62 2002 162 172
17. I. Koch, R. Weil, R. Wolbold, J. Brockmoller, and E. Hustert Interindividual variability and tissue specificity in the expression of cytochrome P4503A mRNA Drug Metab Dispos 30 2002 1108 1114
18. D.K. Turgeon, D.P. Normolle, A.B. Leichtman, T.M. Annesley, and D.E. Smith Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients Clin Pharmacol Ther 52 1992 471 478
19. K.E. Thummel, D.D. Shen, T.D. Podoll, K.L. Kunze, and W.F. Trager Use of midazolam as a human cytochrome P450 probe: in vitro-in vivo correlations in liver transplant patients J Pharmacol Exp Ther 271 1994 549 556
20. C. Ged, M.J. Rouillon, L. Pichard, J. Combalbert, and N. Bressot The increase in urinary excretion of 6β-hydroxy cortisol as a marker of human hepatic cytochrome P450 III A induction Br J Clin Pharmacol 28 1989 373 387
21. S.J. Kovacs, D.E. Martin, D.E. Everitt, S.D. Patterson, and D.K. Jorkasky Urinary 6β-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations Clin Pharmacol Ther 63 1998 617 622
22. S.M. Abel, and D.J. Back Cortisol metabolism in vitro. III. Inhibition of microsomal 6β-hydroxylase and cytosolic 4-ene-reductase J Steroid Biochem Mol Biol 46 1993 827 832
23. A. Lemoine, D. Azoulay, A. Dennison, L. Kiffel, and L. Pichard FK 506 renal toxicity and lack of detectable cytochrome p4503A in the liver graft of a patient undergoing liver transportation Hepatology 20 1994 1472 1477
24. A. Zhiri, M. Wellman-Bednawska, and G. Siest ELISA of 6-beta-hydroxycortisol in human urine: diurnal variations and effects of antiepileptic therapy Clin Chim Acta 157 1986 267 276
25. H. Hosoda, Y. Sakai, and T. Nambara A direct enzyme immunoassay of 6β-hydroxycortisol in human urine Chem Pharm Bull (Tokyo) 29 1981 170 175
26. T. Bienvenu, E. Rey, G. Pons, P. D'Athis, and G. Olive A simple non-invasive procedure for the investigation of cytochrome P450 IIIA-dependent enzymes in humans Int J Clin Pharmacol Ther Toxicol 29 1991 441 445
27. J. Lykkesfeldt, S. Loft, and H.E. Poulsen Simultaneous determination of urinary free cortisol and 6β-hydroxycortisol by high performance liquid chromatography to measure human CYP3A activity J Chromatogr B Biomed Appl 660 1994 23 29
28. K. Inagaki, M. Inagaki, T. Kataoka, I. Sekido, and M.A. Gill A wide interindividual variability of urinary 6β-hydroxycortisol to free cortisol in 487 healthy Japanese subjects in near basal condition Ther Drug Monit 24 2002 722 727
29. A.H. Burstein, W.G. Reiss, E. kantor, and G.D. Anderson Cytochrome P4503A4 activity in premenopausal and postmenopausal women, based on 6β-hydroxycortisol/cortisol ratio Pharmacotherapy 18 1998 1271 1276
30. D.W. Boulton, P. Arnaud, and C.L. Devane A single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratio Br J Clin Pharmacol 51 2001 350 354
31. J.Q. Tran, S.J. Kovacs, T.S. McIntosh, H.M. Davis, and D.E. Martin Morning spot and 24-hour urinary 6β-hydroxycortisol/cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP3A4 induction J Clin Pharmacol 39 1999 487 494
32. Y. Horsmans, J.P. Desager, and C. Harrengt Absence of CYP3A genetic polymorphism assessed by urinary excretion of 6β-hydroxycortisol in 102 healthy subjects on rifampicin Pharmacol Toxicol 71 1992 258 261
33. O.Q. Yin, X. Shi, B. Tonlinson, and M.S. Chow Interindividual and intraindividual variability of the urinary 6 {beta} hydroxycortisol/cortisol ratio in Chinese subjects: implications of its use for evaluating CYP3A activity J Clin Pharmacol 44 2004 1412 1417
34. B.K. Park A direct radioimmunoassay for 6β-hydroxycortisol in human urine J Steroid Biochem 9 1978 963 966
35. K. Nahoul, J. Adeline, F. Paysant, and R. Scholler Radioimmunoassay of plasma and urine in 6β-hydroxycortisol: levels in healthy adults and in hypercortisolemic states J Steroid Biochem 17 1982 343 350
36. K. Matsumura, T. Saito, Y. Takahashi, T. Ozeki, K. Kiyotani, and M. Fujieda Identification of a novel polymorphic enhancer of the human CYP3A4 gene Mol Pharmacol 65 2004 326 334
37. J.K. Lamba, Y.S. Lin, E.G. Schuetz, and K.E. Thummel Genetic contribution to variable human CYP3A-mediated metabolism Adv Drug Deliv Rev 54 2002 1271 1294
38. J.K. Lamba, Y.S. Lin, K. Thummel, A. Daly, and P.B. Watkins Common allelic variants of cytochrome P4503A4 and their prevalence in different populations Pharmacogenetics 12 2002 121 132
39. L. Wojnowski Genetics of the variable expression of CYP3A in humans Ther Drug Monit 26 2004 192 199
40. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4, J Natl Cancer Inst 1998;90:1225-9 [Erratum in: J Natl Cancer Inst 1999;91:1082].
41. M.T. Tayeb, C. Clark, L. Sharp, N.E. Haites, and P.H. Rooney CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia Oncol Rep 9 2002 653 655
42. J. Zhang, P. Kuehl, E.D. Green, J.W. Touchman, and P.B. Watkins The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants Pharmacogenetics 11 2001 555 572
43. A. Westlind-Johnsson, S. Malmebo, A. Johonsson, C. Otter, and T.B. Andersson Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism Drug Metab Dispos 31 2003 755 761
44. S.K. Sy, A. Ciaccia, W. Li, E.A. Roberts, and A. Okey Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression Eur J Clin Pharmacol 58 2002 357 365
45. J.C. Fleishaker, L.K. Pearson, and G.R. Peters Phenytoin causes a rapid increase in 6 beta-hydroxycortisol urinary excretion in humans - a putative measure of CYP3A induction J Pharm Sci 84 1995 292 294
46. M.J. Brodie, and M.A. Dichter Antiepileptic drugs N Engl J Med 18 1996 168 175
47. H. Wietholtz, Th. Zysset, K. Kreiten, D. Kohl, and R. Buchsel Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism Eur J Clin Pharmacol 36 1989 401 406
48. B. Tomlinson, R.B. Young, N.G. MCY, P.J. Anderson, and R. Kay Selective liver enzyme induction by carbamazepine and phenytoin in Chinese epileptics Eur J Clin Pharmacol 50 1996 411 415
49. R.A. Lucas, D.J. Gilfillan, and R.F. Bergstrom A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism Eur J Clin Pharmacol 54 1998 639 643
50. J.J. Mackichan Carbamazepine W.J. Taylor M.H.D. Caviness A textbook for the clinical application of therapeutic drug monitoring 1986 Abbott laboratories Irving, TX 211 224
51. S. Kishino, M. Ogawa, Y. Takekuma, M. Sugawara, and T. Shimamura The variability of liver graft function and urinary 6β-hydroxycortisol to cortisol ratio during liver regeneration in liver transplant recipients Clin Transplant 18 2004 124 129